Abstract：Objective To investigate the effect of human luteinizing hormone (LH) on clinical outcome during in-vitro fertilization or intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET). Methods Clinical data of patients with ovulation induced through long follicle stage regimen at the Reproductive Center of Changsha Maternal and Child Health Hospital from January 2017 to August 2018 were analyzed retrospectively, 188 cycles. The patients were divided into four groups based on whether the LH preparation was added during the ovulation promotion or not: Group A [human menopausal gonadotropin (HMG) group, 72 cycles]: HMG was included in addition to follicle-stimulating hormone (FSH), during ovulation]. Group B (r-LH group, 34 cycles): r-LH was added in addition to FSH in the later stage. Group C (HMG+r-LH group, 51 cycles): HMG was added during ovulation promotion and r-LH group was added in the later stage (no LH group, P < 0.05). Group D (31 cycles): no LH preparation was added. Only FSH was used to promote ovulation until the HCG injection day. Thereafter, the number of eggs, normal fertilization rate, high quality embryo rate, clinical pregnancy rate and embryo implantation rate were compared. Results No significant differences were observed in age, infertility years, blood LH level, number of oocytes acquired, normal fertilization rate and embryo rate among all groups (P > 0. 05). There was highly statistically significant difference in total dose of gonadotropin (Gn) among all groups (P < 0.01), and the total doses of Gn of group A, B, and C were higher than that of group D, the differences were statistically significant (P < 0.05). There was highly statistically significant difference in usage days of Gn among all groups (P < 0.01), and the usage days of Gn of group B and C were longer than those of group A and D, the differences were statistically significant (P < 0.05). There was no statistically significant difference in the number of oocytes, normal fertilization rate, high quality embryo rate and implantation rate in each group (P > 0.05). There was statistically significant difference in clinical pregnancy rate among four groups (P > 0.05), the clinical pregnancy rate of group B were higher than that of those group A and D, the differences were statistically significant (P < 0.05). Conclusion For the patients with ovulation induced by long regimen in early follicular phase, the addition of LH, especially r-LH, exhibited a tendency to increase the clinical pregnancy rate. However, it still needs to be verified through a study based on larger sample size.
夏容 杨盼 李建军 郭海春 张建梅 肖亚玲. 早卵泡期长方案促排卵过程中添加LH制剂对IVF/ICSI临床结局的影响[J]. 中国医药导报, 2020, 17(3): 90-93,109.
XIA Rong YANG Pan LI Jianjun GUO Haichun ZHANG Jianmei XIAO Yaling. Effect of human luteinizing hormone on clinical outcome during in-vitro fertilization or intracytoplasmic sperm injection-embryo transfer. 中国医药导报, 2020, 17(3): 90-93,109.
[1] 李洁，刘倍余.识别促性腺激素释放激素激动剂对垂体-卵巢轴降调节抑制程度及意义[J].生殖医学杂志，2011， 20（S1）：17-20，44.
[2] 李洁，周灿权，钟依平，等，不同小剂量促性腺激素释放激素激动剂在体外受精-胚胎移植中应用的比较[J].中华妇产科杂志，2006，41（4）：269-270.
[3] 庄广伦.卵泡发育与超促排卵[J].生殖医学杂志，2007， 16：226-227.
[4] 李媛.外源性黄体生成素补充治疗在超排卵中的应用[J].生殖医学杂志，2013，22（10）：738-742.
[5] Balasch J，Francisco F. Is luteinizing hormone needed for optimal ovulation induction? [J]. Curr Opin Obstet Gynecol，2002，14（3）：265-274.
[6] Delphine P，Lévy，José M. Navarro，Schattman GL，et al. The role of LH in ovarian stimulation：Exogenous LH：Let′s design the future [J]. Hum Reprod，2000，15（11）：2258-2265.
[7] 朱桂金.黄体生成素在卵泡发育中的作用和黄体生成素峰[J].生殖医学杂志，2007，16（5）：312-313.
[8] 胡玉海.156例不孕症患者性激素水平检测结果评价[J].国际检验医学杂志，2013，34（12）：1593-1594.
[9] Humaidan P，Bungum L，Bungum M，et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation（GnRHa） and recombinant FSH stimulation [J]. Fertil Steril，2002，78（8）：S9.
[10] Beretsos P，Partsinevelos GA，Arabatzi E，et al. “hCG priming” effect in cont rolled ovari an stimulation through a long protocol [J]. Reprod Biol Endocrinol，2009：91-97.
[11] Humaidam P，Bungum L，Bungam M，et al. Ovarian response and pregnancy outcome related to mid—follicular LH levels in women undergoing assisted reproduction with GnRH agonist down—regulation and recombinant FSH stimulation [J]. Hum Reprod，2002，17（8）：2016-2021.
[12] Pezzuto A，Ferrari B，Coppla F，et al. LH supplementation in down regulated women undergoing assisted reproduction with baseline low serum LH levels [J]. Gynecol Endocrinol，2010，26（2）：118-124.
[13] Lahoud R，Ryan J，Illingworth P，et al. Recombinant LH supplementation in patients with a relative reduction in LH levels during IVF/ICSI cycles：A prospective randomized controlled trial [J]. Eur J Obstet Gynecol Reprod Biol，2017，210：300.
[14] 孙莹璞，王芳.降调节对卵子质量的影响[J].生殖医学杂志，2007，16（5）：327-328.
[15] 徐雯，卢伟英，马燕琳，等.高剂量黄体生成素在卵泡期不同时段对体外受精－胚胎移植的影响[J].广东医学，2005，26（10）：1324-1326.
[16] 张春晖，王俊豪，孙洪梅，等.重组促黄体生成素在卵巢储备功能正常患者超促排卵中的应用[J].吉林医学，2013，34（20）：3971-3973.
[17] Gordon UD，Harrison RF，Fawzy M，et al. A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome [J]. Fertil Steril，2001，75（2）：324-331.
[18] 李颂军，沈秀，周睿琼，等.长方案卵泡中/后期添加含活性LH的不同促性腺激素制剂的临床结局比较[J].生殖与避孕，2016，36（5）：372-377.
[19] Hill MJ，Levens ED，Levy G，et al. The use of recombinant luteinizing hormone in patients under going assisted reproductive techniques with advanced reproductive age：a systematic review and meta—analysis [J]. Fertil Steril，2012，97（5）：1108-1114.
[20] De Placido G，Alviggi C，Mollo A，et al. Effects of recombinant LH（r-LH） supplementation during controlled ovarian hyperstimulation（COH） in normogonadotrophic women with an initial inadequate response to recombinant FSH（rFSH） after pituitary downregulation. Clin Endocrinol（Oxf），2004，60（5）：637-643.
2020, Vol. 17 
京公网安备 11010502046598号